GSK/Amplimmune -PD1 trial
- This topic is empty.
Viewing 2 posts - 1 through 2 (of 2 total)
-
Posts
-
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer: http://clinicaltrials.gov/ct2/show/NCT01352884?term=nct+01352884&rank=1 Contact: Margaret Fleming
clinicaltrials@amplimmune.com Trial in 3 locations: Michigan, North Carolina, Tenn.-see link above for speicific locations & contact info.
Thanks James and there is also the Genentech Pd1: http://clinicaltrials.gov/ct2/show/NCT01375842
Viewing 2 posts - 1 through 2 (of 2 total)
- The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.